Affordable Access

Access to the full text

The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma

Authors
  • Shen, Dexin1
  • Fang, Yayun1, 2
  • Zhou, Fenfang1
  • Deng, Zhao1
  • Qian, Kaiyu1, 2, 3
  • Wang, Gang1, 2, 3
  • Xiao, Yu1, 1, 2, 3
  • Ju, Lingao1, 2, 3
  • Wang, Xinghuan1, 3, 4
  • 1 Zhongnan Hospital of Wuhan University, Wuhan, China , Wuhan (China)
  • 2 Human Genetic Resource Preservation Center of Hubei Province, Wuhan, China , Wuhan (China)
  • 3 Chinese Academy of Medical Sciences, Wuhan, China , Wuhan (China)
  • 4 Wuhan University, Wuhan, China , Wuhan (China)
Type
Published Article
Journal
Cancer Cell International
Publisher
Springer (Biomed Central Ltd.)
Publication Date
May 12, 2021
Volume
21
Issue
1
Identifiers
DOI: 10.1186/s12935-021-01969-x
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundCDCA3 is an important component of the E3 ligase complex with SKP1 and CUL1, which could regulate the progress of cell mitosis. CDCA3 has been widely identified as a proto-oncogene in multiple human cancers, however, its role in promoting human bladder urothelial carcinoma has not been fully elucidated.MethodsBioinformatic methods were used to analyze the expression level of CDCA3 in human bladder urothelial carcinoma tissues and the relationship between its expression level and key clinical characteristics. In vitro studies were performed to validate the specific functions of CDCA3 in regulating cell proliferation, cell migration and cell cycle process. Alterations of related proteins was investigated by western blot assays. In vivo studies were constructed to validate whether silencing CDCA3 could inhibit the proliferation rate in mice model.ResultsBioinformatic analysis revealed that CDCA3 was significantly up-regulated in bladder urothelial carcinoma samples and was related to key clinical characteristics, such as tumor grade and metastasis. Moreover, patients who had higher expression level of CDCA3 tend to show a shorter life span. In vitro studies revealed that silencing CDCA3 could impair the migration ability of tumor cells via down-regulating EMT-related proteins such as MMP9 and Vimentin and inhibit tumor cell growth via arresting cells in the G1 cell cycle phase through regulating cell cycle related proteins like p21. In vivo study confirmed that silencing CDCA3 could inhibit the proliferation of bladder urothelial carcinoma cells.ConclusionsCDCA3 is an important oncogene that could strengthen the migration ability of bladder urothelial carcinoma cells and accelerate tumor cell growth via regulating cell cycle progress and is a potential biomarker of bladder urothelial carcinoma.

Report this publication

Statistics

Seen <100 times